CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 188 enrolled
Drug / intervention
Enzalutamide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03809000
NCT03809000Phase 2Active
CompareCT.gov

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features

RTOG Foundation, Inc.·interventional·Posted Jan 18, 2019·Updated Dec 30, 2025

In Brief

A Phase 2 clinical trial evaluating Radiation Therapy, Enzalutamide, and 2 other interventions for Prostate Cancer. Active but no longer recruiting, targeting 188 participants across 108 sites in 2 countries.

Detailed Summary

Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada, United States
CollaboratorsPfizer, Astellas Pharma Inc

Timeline

Phase 2Active
201920202021202220232024202520262027202820292030
First PostedJan 18, 2019
Enrollment StartApr 15, 2019
Primary CompletionApr 7, 2023
Study CompletionSep 15, 2029
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 7.5 years ago

Interventions

Radiation Therapyradiation

daily fractions

Enzalutamidedrug

tablet

Bicalutamidedrug

tablet

GnRH analogdrug

Injection